Cargando…
An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy
Nanoparticles (NPs) are promising drug delivery systems (DDS) for identifying and treating cancer. Active targeting NPs can be generated by conjugation with ligands that bind overexpressed or mutant cell surface receptors on target cells that are poorly or not even expressed on normal cells. Recepto...
Autores principales: | Juan, Alberto, Cimas, Francisco J., Bravo, Iván, Pandiella, Atanasio, Ocaña, Alberto, Alonso-Moreno, Carlos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7558516/ https://www.ncbi.nlm.nih.gov/pubmed/32854255 http://dx.doi.org/10.3390/pharmaceutics12090802 |
Ejemplares similares
-
Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment
por: Juan, Alberto, et al.
Publicado: (2020) -
Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer
por: Cimas, Francisco J., et al.
Publicado: (2020) -
Generation of Antibody-Drug Conjugate Resistant Models
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2021) -
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020) -
Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer
por: Montero, Juan Carlos, et al.
Publicado: (2022)